BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 4147763)

  • 1. Dopaminergic neurons in explants of substantia nigra in culture.
    Coyle JT; Jacobowitz D; Klein D; Axelrod J
    J Neurobiol; 1973; 4(5):461-70. PubMed ID: 4147763
    [No Abstract]   [Full Text] [Related]  

  • 2. Mesencephalic neural stem (progenitor) cells develop to dopaminergic neurons more strongly in dopamine-depleted striatum than in intact striatum.
    Nishino H; Hida H; Takei N; Kumazaki M; Nakajima K; Baba H
    Exp Neurol; 2000 Jul; 164(1):209-14. PubMed ID: 10877931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
    Sajadi A; Bauer M; Thöny B; Aebischer P
    J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
    Rosenblad C; Kirik D; Björklund A
    Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain.
    Beck KD; Valverde J; Alexi T; Poulsen K; Moffat B; Vandlen RA; Rosenthal A; Hefti F
    Nature; 1995 Jan; 373(6512):339-41. PubMed ID: 7830767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra.
    Salvatore MF; Zhang JL; Large DM; Wilson PE; Gash CR; Thomas TC; Haycock JW; Bing G; Stanford JA; Gash DM; Gerhardt GA
    J Neurochem; 2004 Jul; 90(1):245-54. PubMed ID: 15198683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
    Matsuura K; Makino H; Ogawa N
    Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats.
    Lu X; Hagg T
    J Comp Neurol; 1997 Nov; 388(3):484-94. PubMed ID: 9368855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crossed nigrostriatal dopaminergic pathway.
    Su HS
    Chin Med J (Engl); 1986 Mar; 99(3):215-20. PubMed ID: 3095047
    [No Abstract]   [Full Text] [Related]  

  • 13. Intrastriatal infusions of brain-derived neurotrophic factor: retrograde transport and colocalization with dopamine containing substantia nigra neurons in rat.
    Mufson EJ; Kroin JS; Sobreviela T; Burke MA; Kordower JH; Penn RD; Miller JA
    Exp Neurol; 1994 Sep; 129(1):15-26. PubMed ID: 7523178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.
    Quik M; Parameswaran N; McCallum SE; Bordia T; Bao S; McCormack A; Kim A; Tyndale RF; Langston JW; Di Monte DA
    J Neurochem; 2006 Sep; 98(6):1866-75. PubMed ID: 16882311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of GDNF in neuronal protection against 6-OHDA-induced parkinsonism following intracerebral transplantation of fetal kidney tissues in adult rats.
    Borlongan CV; Zhou FC; Hayashi T; Su TP; Hoffer BJ; Wang Y
    Neurobiol Dis; 2001 Aug; 8(4):636-46. PubMed ID: 11493028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of acute and chronic administration of 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline on the function of the nigrostriatal dopaminergic system in rats.
    Lorenc-Koci E; Antkiewicz-Michaluk L; Kamińska A; Lenda T; Zieba B; Wierońska J; Smiałowska M; Schulze G; Rommelspacher H
    Neuroscience; 2008 Oct; 156(4):973-86. PubMed ID: 18809471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures.
    Kress GJ; Reynolds IJ
    Neurobiol Dis; 2005 Dec; 20(3):639-45. PubMed ID: 15996475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
    Cunningham LA; Su C
    Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.
    Engler H; Doenlen R; Riether C; Engler A; Niemi MB; Besedovsky HO; del Rey A; Pacheco-López G; Feldon J; Schedlowski M
    Brain Behav Immun; 2009 May; 23(4):518-26. PubMed ID: 19486644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.